Skip to main content
OpenTrials
Completed

NCT Number: NCT05299086

As Needed Versus Regular Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis

Allergic rhinitis in children is common. According to the international study of asthma and allergies in childhood (ISAAC) phase III, the global prevalence of allergic rhinitis among children is increasing to 40.1% and the prevalence of allergic rhinitis in Bangkok area in 2018, among children aged 6-7 and 13-14 years was 16.32%. This disease is a global health problem affecting quality of life of patients in daily life, work, study and sleep.

Intranasal corticosteroid is the most effective treatment for allergic rhinitis. From real world evidence; most of allergic rhinitis patient use the drug when symptoms worsen. In children, the use of intranasal corticosteroid may cause minor local side effects such as dryness, burning sensation or epistaxis. In some intranasal corticosteroid, long-term use may result in decreased growth compared to placebo which make parents concern.

The investigators interested in studying the efficacy of intranasal corticosteroid comparing between daily use and as needed use in children with allergic rhinitis. To study the appropriate form of treatment to increase cooperation. Patient will have a better quality of life and reduce the risk of side effects from prolonged use of intranasal corticosteroid. From the literature review, it was found that most studies were conducted among adult patients with seasonal allergic rhinitis In Thailand in 2020, Thongngam et al. studied the efficacy of intranasal corticosteroid was compared between daily use and as needed use in adult patients with perennial allergic rhinitis. The results of the study concluded that the daily use group can reduced more TNSS (total nasal symptoms score) but was not statistically significant and had a greater increase in peak nasal inspiratory flow (PNIF) compared to as needed group. Interestingly, the quality of life assessment (RCQ-36 score) in both2 groups improved equally, In as needed group, the cumulative dose was 51% lower than the daily dose group.

The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Perennial Allergic Rhinitis Child, Only Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Nose Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Respiratory Tract Diseases Rhinitis Rhinitis, Allergic Rhinitis, Allergic, Perennial

Age range

6 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University

Bangkok, 10700, Thailand

About this study

8 week Double-blinded placebo controlled randomized controlled trial to compare the efficacy between as-needed and regular use of INCS in children with perennial allergic rhinitis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children patient (age 6 - 18 yr)
  • Mild persistent, Moderate to severe intermittent and persistent perennial allergic rhinitis
  • Rhinitis proven sensitization to aeroallergen by positive skin prick test or specific IgE result within 12 month before study recruitment
  • Mean TNSS = 4 during 7 day duration before randomization (after a washout period, discontinuation of the medications listed in exclusion criteria

Exclusion criteria

  • Patients with rhinosinusitis, nasal polyps, or significant deviated nasal septum
  • Patients with a history of uncontrolled asthma, chronic lung disease, cardiovascular, hepatic, or renal diseases
  • Patients taking oral or nasal decongestants within 7 d
  • Patients taking INCS within 4 week
  • Patients taking systemic corticosteroid within 8 week
  • Patients taking H1 antihistamine within 1 week
  • Patients taking antileukotriene within 4 week
  • Patients who were currently or previously treated with allergen immunotherapy
  • Patients with a history of upper respiratory tract infection within 14 d
  • Patients with primary and secondary immune deficiency

Treatment and study plan

Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)

Drug

The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.

Other names: As needed Fluticasone furoate nasal spray, Regular Fluticasone furoate nasal spray

Primary outcomes

  1. TNSS (total nasal symptoms score)

    Time frame: 8 week

    change in TNSS 4 nose symptoms (sneezing, itching nose, watery running nose and blockage) The minimum score is 0 and maximum score is 3 each symptoms (__/12) higher scores mean worse outcome.

  2. VAS score (Visual analog scale score for rhinitis)

    Time frame: 8 week

    change in VAS score Score is 0 - 10 mm higher scores mean worse outcome.

Secondary outcomes

  1. Ocular symptoms score

    Time frame: 8 week

    Change in ocular symptoms score 2 eye symptoms (tearing eyes, itching eyes/red eyes) The minimum score is 0 and maximum score is 3 each symptoms (__/6) Higher scores mean worse outcome.

  2. Peak nasal inspiratory flow (PNIF)

    Time frame: 8 week

    Change in peak nasal inspiratory flow (PNIF)

  3. Rhinoconjunctivitis Quality of Life-36 Questionnaire score (RCQ-36)

    Time frame: 8 week

    Change in rhinoconjunctivitis Quality of Life-36 Questionnaire score (RCQ-36)

  4. Medications score Medications score

    Time frame: 8 week

    Change in medications score Medication score Oral and/or topical (eyes or nose) non-sedative H1 antihistamines (H1A)=1 Intranasal corticosteroids (INS) with/without H1A =2 Oral corticosteroids with/without INS, with/without H1A =3 Total daily medication score (dMS) 0-3 Higher scores mean worse outcome.

  5. Nasal FENO (nasal nitric oxide)

    Time frame: 8 week

    Change in nasal FENO

  6. Nasal cytology

    Time frame: 8 week

    Change in nasal cytology

    Grading Nasal Cytograms A. Epithelial cells Normal morphology N Abnormal morphology A Ciliocytophthoria CCP

    B. Eosinophils, neutrophils 0* None 0 0.1-1.0* ½+ 1.1-5.0* 1+ 6.0-15.0* 2+ 16.0-20.0* 3+ >20.0* 4+

    C. Basophilic cells 0 None 0 0.1-0.3* ½+ 0.4-1.0* 1+ 1.1-3.0* 2+ 3.1-6.0* 3+ >6.0* 4+

    D. Bacteria N/A+ None 0 N/A+ 1+ N/A+ 2+ N/A+ 3+ N/A+ 4+

    E. Goblet cells# 0-24% 1+ 25-49% 2+ 50-74% 3+ 75-100% 4+

    • Mean of cells per 10 high power fields (x1000). + Note presence of intracellular bacteria. # Ratio of goblet cells to epithelial cells, expressed as percent.

  7. Combined symptom and medication score

    Time frame: 8 week

    Change in combined symptom and medication score Cumulative of (nasal symptoms score + ocular symptoms score)/3 and medication score The minimum score is 0 maximum score is 6, (__/6) Higher scores mean worse outcome.

    Pfaar et al., EAACI Position Paper: 'clinical outcomes used in allergen immunotherapy trials, Allergy 69 (2014) 854-867

  8. Correlation VAS versus TNSS, PNIF and RCQ-36

    Time frame: 8 week

    VAS score (Visual analog scale score for rhinitis) total nasal symptoms score Peak nasal inspiratory flow (PNIF) Rhinoconjunctivitis Quality of Life-36 Questionnaire score (RCQ-36)

  9. Cumulative INCs dose

    Time frame: 8 week

    weight the nasal spray bottles (both Fluticasone furoate nasal spray and normal saline nasal spray) on digital scale each visit and record to compare INCS used in each group

Sponsors and collaborators

Lead sponsor

Mahidol University

Other

Registry information

Official study title

As Needed Versus Regular Use of Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis: A Randomized Controlled Trial

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Mar 28, 2022
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.